Tamoxifen Quandary; Promising Cancer Drug May Hide a Troubling Dark Side

By Raloff, Janet | Science News, April 25, 1992 | Go to article overview

Tamoxifen Quandary; Promising Cancer Drug May Hide a Troubling Dark Side


Raloff, Janet, Science News


In January, an international team of researchers published a huge analysis of the success of various post-surgical, or adjuvant, therapies for breast cancer. Drawing on 133 randomized trials from around the world, their data identified tamoxifen -- a synthetic hormone -- as the ascendant star.

Unlike standard chemotherapeutic agents -- which kill dividing cells throughout the body, not just in the cancer -- tamoxifen kills nothing. It routs cancers by starving them of the estrogen that can promote their growth.

Hailed as nothing less than a wonder drug, tamoxifen has proved so successful in stalling or preventing breast cancer recurrence that researchers in the United States stand poised to begin large-scale trials of the drug this week in healthy women at high risk of the disease. A related trial could begin any day in the United Kingdom, with others slated in Europe and Australia. Their goal: prevention of breast cancer -- the most common malignancy in women.

New toxicological studies, however, hint that tamoxifen may itself cause cancer. These findings are seeding doubts about the wisdom of administering the potent anti-estrogenic drug for years -- perhaps for life -- to healthy women.

The new data have already held up the U.K. cancer-prevention trial involving tamoxifen. On March 12, as the study's leaders planned to begin recruiting an estimated 13,000 additional volunteers for a scaled-up five-year program, Britain's Medical Research Council (MRC) withdrew its support for the study as currently designed, pending further toxicological studies. The two remaining sponsors -- the Imperial Cancer Research Fund and the Cancer Research Campaign -- decided to continue the trial on their own, provided the U.K.'s Department of Health approves. At press time, that agency was taking a second look at the study design.

A U.S. tamoxifen trial for breast cancer prevention, funded by the National Cancer Institute (NCI), remains on track. NCI has scheduled a press conference for April 29 to announce details of this study, slated to eventually involve 16,000 healthy, high-risk women age 35 and over, half of whom will get the drug.

MRC Secretary Dai A. Rees explained his agency's decision to withdraw from the U.K. study in the March 28 BRITISH MEDICAL JOURNAL. Unpublished data by tamoxifen's manufacturer indicate that the drug induces liver tumors in rats, he notes. Because of the way it accumulates in the human body, doses of the drug responsible for producing cancers in rats appear "similar to those to be used in the trial," Rees says. As a result, "there is no dose or safety margin."

Rees also cites a study reported in the March 1 CANCER RESEARCH showing that tamoxifen produces potentially carcinogenic DNA alterations -- known as adducts -- in the livers of at least two types of rodents. Finally, though researchers have studied tamoxifen's effects in thousands of women, few of those patients have received the drug for more than five to seven years; that's less time than it usually takes for carcinogens to induce liver tumors in humans, Rees notes.

Worldwide, breast cancer rates are increasing (SN: 4/21/90, p.245). This disease, which will strike one in nine U.S. and Canadian women sometime during their lives, kills almost 45,000 each year in the United States alone.

MRC "has no wish to spread alarm among women taking tamoxifen for proved breast cancer," Rees says; for them, tamoxifen "is a well-tried and effective treatment" (see sidebar). However, until potentially life-threatening side effects can be ruled out, he says, MRC cannot justify administering this drug, as planned, to healthy women under age 40.

But not all researchers regard the new animal data as particularly revealing about tamoxifen's threat to humans. "Rat experiments seem to be the first stage, used to try to decide whether to use a drug or not," says Richard Peto, director of the cancer studies unit at Oxford University in England. …

The rest of this article is only available to active members of Questia

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Tamoxifen Quandary; Promising Cancer Drug May Hide a Troubling Dark Side
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Help
Full screen

matching results for page

    Questia reader help

    How to highlight and cite specific passages

    1. Click or tap the first word you want to select.
    2. Click or tap the last word you want to select, and you’ll see everything in between get selected.
    3. You’ll then get a menu of options like creating a highlight or a citation from that passage of text.

    OK, got it!

    Cited passage

    Style
    Citations are available only to our active members.
    Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

    1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

    Cited passage

    Thanks for trying Questia!

    Please continue trying out our research tools, but please note, full functionality is available only to our active members.

    Your work will be lost once you leave this Web page.

    Buy instant access to save your work.

    Already a member? Log in now.

    Author Advanced search

    Oops!

    An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.